- Home
- IFRX vs RSF Comparison
IFRX vs RSF Comparison
Compare IFRX & RSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- RSF
- Stock Information
- Founded
- IFRX 2007
- RSF 2016
- Country
- IFRX Germany
- RSF United States
- Employees
- IFRX N/A
- RSF N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- RSF Investment Managers
- Sector
- IFRX Health Care
- RSF Finance
- Exchange
- IFRX Nasdaq
- RSF Nasdaq
- Market Cap
- IFRX 53.5M
- RSF 49.1M
- IPO Year
- IFRX 2017
- RSF N/A
- Fundamental
- Price
- IFRX $1.60
- RSF $14.83
- Analyst Decision
- IFRX Strong Buy
- RSF
- Analyst Count
- IFRX 4
- RSF 0
- Target Price
- IFRX $7.75
- RSF N/A
- AVG Volume (30 Days)
- IFRX 577.2K
- RSF 11.8K
- Earning Date
- IFRX 08-07-2025
- RSF 01-01-0001
- Dividend Yield
- IFRX N/A
- RSF 10.61%
- EPS Growth
- IFRX N/A
- RSF N/A
- EPS
- IFRX N/A
- RSF N/A
- Revenue
- IFRX $191,224.00
- RSF N/A
- Revenue This Year
- IFRX N/A
- RSF N/A
- Revenue Next Year
- IFRX $1,336.36
- RSF N/A
- P/E Ratio
- IFRX N/A
- RSF N/A
- Revenue Growth
- IFRX 54.36
- RSF N/A
- 52 Week Low
- IFRX $0.71
- RSF $14.81
- 52 Week High
- IFRX $2.82
- RSF $16.23
- Technical
- Relative Strength Index (RSI)
- IFRX 89.35
- RSF 65.90
- Support Level
- IFRX $0.82
- RSF $14.70
- Resistance Level
- IFRX $0.96
- RSF $14.90
- Average True Range (ATR)
- IFRX 0.11
- RSF 0.05
- MACD
- IFRX 0.06
- RSF 0.01
- Stochastic Oscillator
- IFRX 100.00
- RSF 72.43
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.